ReproCell

ReproCell Revenue per Employee

The Revenue per Employee of ReproCell (4978.T) as of Oct 9, 2026 is 20.12 M JPY. In the previous year, Revenue per Employee was 26.83 M JPY — a change of -25.02% (lower).

Revenue per Employee

20.12 MJPY

YoY

-25.02%

Last updated:

Revenue per Employee of ReproCell is 2026 20.12 M JPY. Revenue per Employee of ReproCell was 2025 26.83 M JPY. It decreases by -25.02% lower compared to the previous year.

The ReproCell Revenue per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Employee
Date
Revenue per Employee
Jan 1, 2019
9.81 M JPY
Jan 1, 2020
10.81 M JPY
Jan 1, 2021
11.59 M JPY
Jan 1, 2022
20.13 M JPY
Jan 1, 2023
26.61 M JPY
Jan 1, 2024
21.86 M JPY
Jan 1, 2025
26.83 M JPY
Jan 1, 2026
20.12 M JPY
The ReproCell Revenue per Employee history
YEARRevenue per EmployeeYoY
20.12 MJPY-25.02%
26.83 MJPY+22.74%
21.86 MJPY-17.83%
26.61 MJPY+32.16%
20.13 MJPY+73.72%
11.59 MJPY+7.20%
10.81 MJPY+10.23%
9.81 MJPY+17.52%
8.34 MJPY-26.36%
11.33 MJPY+17.95%
9.61 MJPY+88.07%
5.11 MJPY+23.01%
4.15 MJPY—
Access this data via the Eulerpool API

ReproCell Stock analysis

What does ReproCell do? ReproCell, Inc. is a company that was founded in 2003 and specializes in the research and manufacture of cell cultures. The company is based in Yokohama, Japan and operates worldwide. Its business model includes providing services and products to support research and development activities in the field of regenerative medicine and cell therapy. The company is divided into three main divisions: the Biorepository Division, which provides human cells and tissues for research purposes; the Cell Manufacturing Division, which develops production processes for cell therapy products; and the Drug Discovery Division, which supports drug development through screening and in vitro testing. ReproCell offers a variety of cell cultures, including stem cells from various sources, as well as related media, reagents, and tools for cultivation and application. In addition, the company offers services in cell therapy production, working closely with customers to provide customized and high-quality therapies. ReproCell also supports drug and compound research through screening and in vitro testing, with various platforms available for the identification and evaluation of new compounds. The company has a history of growth and has become a leading player in the field of cell culture and cell therapy production. In conclusion, ReproCell plays a significant role in regenerative medicine and cell therapy production, offering a wide range of products and services to support research and development in these areas. It is poised to continue its growth and contribute to the development of new therapies in the future. ReproCell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ReproCell stock

Revenue per Employee of ReproCell is 20.12 M JPY in 2026.

Revenue per Employee of ReproCell changed from 26.83 M JPY to 20.12 M JPY, representing a -25.02% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Revenue per Employee ReproCell since 2006 – with annual values, charts, and detailed analysis.

Revenue per employee measures workforce productivity by dividing total revenue by the number of employees. Higher values indicate more efficient operations.

Revenue per Employee's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Revenue per Employee's ReproCell historically and in real time.

Access this data via the Eulerpool API

Workforce — ReproCell

All Key Metrics — ReproCell